

Astellas at ASH Annual Meeting 2020
Presentation Overview

Type	Abstract Title	Abstract Number
	Gilteritinib	
Oral Presentation	A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results	24
Oral Presentation	Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib	334
Oral Presentation	Phase 3, Multicenter, Open-Label Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy	27
Oral Presentation	Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial	213
Oral Presentation	Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study	333
E-poster	Clinical Outcomes Following Treatment with Gilteritinib or Quizartinib in Patients with Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia	995
E-poster	Streamline – Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes	2826
E-poster	Pain and Opioid Use in Patients With FLT3 Mutation–Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes From the ADMIRAL Trial	2568
Online-only	Real-World Use of FLT3-TKIs in R/R FLT3-Mutated AML in the United States	4413